LXRX — Lexicon Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $243.87m
- $149.73m
- $31.08m
- 42
- 14
- 51
- 28
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.58 | ||
| Price to Tang. Book | 2.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -94.91% | ||
| Return on Equity | -86.09% | ||
| Operating Margin | -568.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 24 | 0.3 | 0.14 | 1.2 | 31.08 | 9.64 | 14.13 | -37.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Directors
- Raymond Debbane CHM (66)
- Jeffrey Wade PRE (56)
- Lonnel Coats CEO (56)
- Alan Main EVP (67)
- Craig Granowitz SVP (57)
- Kristen Alexander VFN (53)
- Brian Crum VPR (48)
- Philippe Amouyal IND (62)
- Samuel Barker IND (78)
- Robert Lefkowitz IND (77)
- Alan Nies IND (83)
- Frank Palantoni IND (63)
- Christopher Sobecki IND (62)
- Judith Swain IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- July 7th, 1995
- Public Since
- April 7th, 2000
- No. of Shareholders
- 273
- No. of Employees
- 103
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 363,178,000
- Address
- 2445 Technology Forest Blvd, 11Th Floor, THE WOODLANDS, 77381
- Web
- https://www.lexpharma.com/
- Phone
- +1 2818633000
- Auditors
- Ernst & Young LLP
Upcoming Events for LXRX
Lexicon Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Lexicon Pharmaceuticals Inc Earnings Release
Q3 2025 Lexicon Pharmaceuticals Inc Earnings Release
Q3 2025 Lexicon Pharmaceuticals Inc Earnings Release
Similar to LXRX
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Lexicon Pharmaceuticals share price?
As of Today at 21:44 UTC, shares in Lexicon Pharmaceuticals are trading at $0.54. This share price information is delayed by 15 minutes.
How has the Lexicon Pharmaceuticals share price performed this year?
Shares in Lexicon Pharmaceuticals last closed at $0.54 and the price had moved by -70.91% over the past 365 days. In terms of relative price strength the Lexicon Pharmaceuticals share price has underperformed the S&P500 Index by -74.11% over the past year.
What are the analyst and broker recommendations for Lexicon Pharmaceuticals?
The overall consensus recommendation for Lexicon Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lexicon Pharmaceuticals dividend yield?
Lexicon Pharmaceuticals does not currently pay a dividend.
Does Lexicon Pharmaceuticals pay a dividend?
Lexicon Pharmaceuticals does not currently pay a dividend.
When does Lexicon Pharmaceuticals next pay dividends?
Lexicon Pharmaceuticals does not currently pay a dividend.
How do I buy Lexicon Pharmaceuticals shares?
To buy shares in Lexicon Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lexicon Pharmaceuticals?
As of the previous close price of $0.54, shares in Lexicon Pharmaceuticals had a market capitalisation of $194.37m.
Where are Lexicon Pharmaceuticals shares listed?
Here are the trading details for Lexicon Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: LXRX
What kind of share is Lexicon Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Lexicon Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lexicon Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Lexicon Pharmaceuticals is $2.58. That is 382.06% above the last closing price of $0.54.
Analysts covering Lexicon Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.34 for the next financial year.
Find out moreWhat is the trend in the Lexicon Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lexicon Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -45.72%.
As of the last closing price of $0.54, shares in Lexicon Pharmaceuticals were trading -48.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lexicon Pharmaceuticals PE Ratio?
The Lexicon Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals' management team is headed by:
- Raymond Debbane - CHM
- Jeffrey Wade - PRE
- Lonnel Coats - CEO
- Alan Main - EVP
- Craig Granowitz - SVP
- Kristen Alexander - VFN
- Brian Crum - VPR
- Philippe Amouyal - IND
- Samuel Barker - IND
- Robert Lefkowitz - IND
- Alan Nies - IND
- Frank Palantoni - IND
- Christopher Sobecki - IND
- Judith Swain - IND